Items where authors include "Taylor, C.A."
![[up]](/style/images/multi_up.png)
Up a levelArticle
Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370
Wright-Hughes, A. orcid.org/0000-0001-8839-6756, Ow, P.-L., Alderson, S.L. et al. (11 more authors) (2025) Predictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial. Gut. ISSN 0017-5749
Ion, M.C., Bloomer, C.C., Bărăscu, T.I. et al. (88 more authors) (2024) World of Crayfish™: a web platform towards real-time global mapping of freshwater crayfish and their pathogens. PeerJ, 12 (10). e18229. ISSN 2167-8359
Wright-Hughes, A. orcid.org/0000-0001-8839-6756, Ford, A.C. orcid.org/0000-0001-6371-4359, Alderson, S.L. orcid.org/0000-0002-5418-0495 et al. (19 more authors) (2024) Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT. Health Technology Assessment, 28 (66). ISSN 1366-5278
Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587
Ford, A.C., Wright-Hughes, A., Alderson, S.L. et al. (65 more authors) (2023) Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. ISSN 0140-6736
Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736